New math on drug cost-effectiveness

New England Journal of Medicine

Volumn 373, Issue 19, 2015, Pages 1797-1799

  Bach, Peter B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; BIOSIMILAR AGENT; DRUG; EVEROLIMUS; GENERIC DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIVOLUMAB; PAZOPANIB; SACUBITRIL; SORAFENIB; VALSARTAN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER PATIENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEPATITIS C; HUMAN; KIDNEY CARCINOMA; MEDICARE; PRIORITY JOURNAL; REVIEW; UNITED STATES; CARCINOMA, RENAL CELL; COST BENEFIT ANALYSIS; ECONOMICS; KIDNEY NEOPLASMS; TRENDS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUGS, GENERIC; HUMANS; KIDNEY NEOPLASMS; MEDICARE; UNITED STATES;

EID: 84946606252     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1512750     Document Type: Review

References (5)

1. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014;32: 306-11.
2. Pollack A. Genentech caps cost of cancer drug for some patients. New York Times. October 12, 2006 (http://www.nytimes.com/2006/10/12/business/12drug.html?-r=0).
3. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect 2015;29: 139-62.
4. Herper M. The FDA is basically approving everything. Here's the data to prove it. Forbes. August 23, 2015 (http://www.forbes.com/sites/matthewherper/2015/08/20/the -fda-is-basically-Approving-everything-heres -The-data-To-prove-it).
5. Evaluating the value of new drugs and devices. Boston: Institute for Clinical and Economic Review, 2015.